Download PDF
Semin Neurol 2001; 21(4): 417-424
DOI: 10.1055/s-2001-19413
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Pearls and Pitfalls of Clinical Trial Investigation: Should I Get Involved in the Drug Development Process?

Amy S. Chappell
  • Lilly Research Laboratories, Lilly Corporate Center, and Department of Neurology, Indiana University Medical School, Indianapolis, Indiana
Further Information

Publication History

Publication Date:
02 January 2002 (online)

    Permissions and Reprints

ABSTRACT

The revolution in neurological therapeutics means that an increasing number of neurologists will have the opportunity to participate in a drug development process that is long and complicated. The opportunity provides challenges as well as rewards, and should be undertaken only after thoughtful review of the Clinical Investigator's Brochure and protocol. Key questions that the neurologist should address prior to participation are reviewed herein.

KEYWORD

Clinical trials - drug development

REFERENCES

  • 1 Posvar E, Sedman A. New drugs: first time in man.  J Clin Pharmacol . 1989;  29 961-966
    PubMedGoogle Scholar
  • 2 Faries D. Practical modifications of the continual reassessment method for phase1 cancer clinical trials.  J Biopharm Statistics . 1994;  4 147-164
    PubMedGoogle Scholar
  • 3 Goldstein D, Potter W. Determination of appropriate dosage in clinical development. In: Balant L, Benitez J, Dahl S, Gram L, Pinder R, Potter W, eds. Clinical Pharmacology in Psychiatry: Finding the Right Dose of Psychotropic Drugs Luxembourg: Office for Official Publications of the European Communities 1997: 305-322
    Google Scholar
  • 4 Sang C, Hostetter M, Gracely R. Effects of an AMPA/Kainate antagonist in humans: reduction of hyperalgesia at subsedative doses.  Anesthesiology . 1998;  89 1060-1067
    CrossrefPubMedGoogle Scholar
  • 5 Barinaga M. Neurotrophic factors enter the clinic.  Science . 1994;  264 772-774
    PubMedGoogle Scholar
  • 6 Partridge W, Kang Y, Buciak J. Transport of human recombinant brainderived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery.  Pharm Res . 1994;  11 738-746
    CrossrefPubMedGoogle Scholar
  • 7 Partridge W. CNS drug design based on principles of blood-brain barrier transport.  J Neurochem . 1998;  70 1781-1792
    PubMedGoogle Scholar
  • 8 Sramek J, Eldon M, Posvar E. Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of Cl-1007 in patients with schizophrenia.  Psychopharm Bulletin . 1998;  34 93-99
    PubMedGoogle Scholar
  • 9 Cutler N, Sramek J. The bridging concept: optimizing dose for phase II/III in Alzheimer's disease.  Neurodegeneration . 1996;  5 511-514
    CrossrefPubMedGoogle Scholar
  • 10 Sramek J, Cutler N, Kurtz N, Murphy M, Carta A. Optimizing the Development of Antipsychotic Drugs.  Chichester, England: John Wiley & Sons 1997: 101-126
    Google Scholar
  • 11 Sramek J, Fresquet A, MarionLandais G. Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study.  J Clin Psychopharmacol . 1987;  7 436-437
    PubMedGoogle Scholar
  • 12 Goldstein D, Wang O, Saper J, Stoltz R, Silberstein S, Mathew N. Ineffectiveness of neurokinin1 antagonist in acute migraine: a crossover study.  Cephalalgia . 1997;  17 785-790
    CrossrefPubMedGoogle Scholar
  • 13 Lenert L, Markowitz D, Blaschke T. Primum non nocere?.  <~>Valuing of the risk of drug toxicity in therapeutic decision making. Clinical Pharm Ther . 1993;  53 285-291
    PubMedGoogle Scholar
  • 14 Payne R, Pasternak G. Pain. In: Johnston M, MacDonald R, Young A, eds. Principles Of Drug Therapy In Neurology New York: F.A. Davis Company 1992: 268-301
    Google Scholar
  • 15 Irish W, Macdonald D, Cairncross G. Measuring bias in uncontrolled brain tumor trials: to randomize or not to randomize?.  Can J Neurol Sci . 1997;  24 307-312
    PubMedGoogle Scholar
  • 16 Stone L, Frank J, Albert P. Characterization of MRI response to treatment with interferon beta-lb: contrast enhancing MRI lesion frequency as a primary outcome measure.  Neurology . 1997;  49 862-869
    PubMedGoogle Scholar
  • 17 Lublin F, Reingold S, and the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis.  Neurology . 1997;  48 572-574
    PubMedGoogle Scholar
  • 18 Honig P, Wortham D, Zamani K, Conner D, Mullin J, Cantilena L. Terfenadine-ketoconazole interaction.  JAMA . 1993;  12 1513-1518
    PubMedGoogle Scholar
  • 19 Theodore W, Raubertas R, Porter R. Felbamate: a clinical trial for complex partial seizures.  Epilepsia . 1991;  32 392-397
    PubMedGoogle Scholar
  • 20 Ring B, Binkley S, Wrightman S A. In vitro interaction of LY300164 with human cytochrome P450 CYP3A, CYP2C9, and CYP1A2. Lilly Clinical Investigator's Brochure. Indianapolis: Eli Lilly & Company 2000
    Google Scholar
  • 21 Jewell H, Lucas R. LY300164 single and multiple dose pharmacokinetics and initial one-week experience in patients with chronic epilepsy. Lilly Clinical Investigator's Brochure. Indianapolis: Eli Lilly & Company 2000
    Google Scholar
      >